Docter Inc. and Aimfinity Investment Corp. I Announce Definitive Merger Agreement

Winston & Strawn is representing Docter Inc., a Taiwanese non-invasive blood glucose watch developer, in its announced definitive merger agreement with Aimfinity Investment Corp. I., a publicly traded special purpose acquisition company. Announced today, they have entered a definitive merger agreement, pursuant to which a newly established subsidiary of Aimfinity will become a publicly listed company combining Aimfinity and Docter upon the closing of the transaction. The proposed merger consideration is US$60M, payable by newly-issued shares of the Combined Company valued at US$10 per share. Additional earnout shares may be issuable to Docter stockholders after closing, upon achievement of certain sales targets in 2024 and 2025. Following the closing, assuming no redemption by existing public shareholders of Aimfinity, the Aimfinity shareholders will have approximately 51.92% equity interest in the Combined Company and the current Docter stockholders will have approximately 48.08% equity interest in the Combined Company. If, however, there is a maximum redemption of existing public shareholders of Aimfinity resulting in remaining balance of trust account of US$5M, the Aimfinity shareholders will have approximately 29.45% equity interest in the Combined Company and the Docter stockholders will have approximately 70.55% equity interest in the Combined Company.